Merrimack (MACK) Buy Rating Reiterated at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Merrimack (MACK) Buy Rating Reiterated at Cantor Fitzgerald
September 24, 2014 8:12 AM EDT
Merrimack Pharmaceuticals (Nasdaq: MACK) shares are ripping in early trading following news that the company entered an exclusive agreement with Baxter International Inc. (NYSE: BAX).
According to an... More
September 24, 2014 7:01 AM EDT
Baxter International Inc. (NYSE: BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.'' Through the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan, and Merrimack retains commercialization rights in the United States; the rights in Taiwan are held separately.
MM-398 is an investigational drug candidate for which Merrimack is preparing a New Drug Application in the United... More
